10.03.25 -- Why Pharma, Medical Device Risks Must Be Analyzed By Their Risk Mechanisms

Unlock the keys to successful First-in-Human studies with Quotient. This webinar reveals how expert-designed SAD/MAD trials, flexible CMC strategies, and smart regulatory planning accelerate proof-of-concept while avoiding costly setbacks. Gain insider insights on biomarkers, patient recruitment, and data integration—plus real-world case studies across rare diseases, obesity, CNS, and inflammation. De-risk early development and keep your program moving forward. Click here to learn more.

Explore the transformative potential of pharmaceutical spray drying in improving drug formulation, bioavailability, and delivery through versatile and innovative applications.

Here, we outline five key factors that drive a seamless and efficient technology transfer, highlighting how technical expertise, customer focus, and operational flexibility are crucial to CDMO success.

A supply chain expert with decades of experience says that "from a pure supply chain perspective, we always try to "have universal drug substance, universal drug product and try to differentiate in packaging." But that doesn't always work out ... 

CDMO focused on active pharmaceutical ingredients (APIs) have long been vital components in the supply chain. Today, they are more than your enablers. CDMO have become strategic actors helping to reshape global outsourcing markets. A new report focuses on the new forces raising their importance.

A focus on spray-drying expertise in pulmonary and nasal powder development highlights why it is vital to choose the right CDMO.

To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

Kneat: Data Ready offers not only templates, but a validated out-of-the-box configuration that you can tailor to your business needs. Implement your Kneat instance in less than half the time.

With nine manufacturing sites across five countries, our network supports the discovery of new chemical entities through commercial programs, while simplifying outsourcing with regulatory expertise.